WASHINGTON--(BUSINESS WIRE)--Kit Check™, the leader in automated medication management solutions for hospitals, today announced that its Bluesight for Controlled Substances (Bluesight) diversion prevention and controlled substance management solution has been recognized by leading analyst firm KLAS Research in its next-generation solution report. The inaugural report from KLAS, “Drug Diversion Monitoring: An Early Look at Emerging Vs. Established Technology,” highlights hospitals and health systems’ need for drug diversion monitoring technology amidst the national opioid epidemic.
One of only two reviewed solutions categorized as “next generation” in the market with significant customer adoption, Kit Check’s Bluesight for Controlled Substances received an overall performance rating of 93.2* out of 100, noting that its customers are highly satisfied overall with the system, which integrates multiple data sources into an easy-to-use dashboard that simplifies drug-diversion investigations. The report states that Kit Check sets their customers up for success by setting clear expectation, providing training and helping organizations optimize the system. KLAS found that 100 percent* of Kit Check’s customers would purchase the solution again, plan to have it as part of their long-term strategy for drug diversion prevention and control, and state that the company keeps its promises and does not “nickel-and-dime” its customers. Easily integrated with electronic medical records (EMRs), Bluesight for Controlled Substances provides customers with comprehensive behavior analysis necessary for thorough investigations.
“KLAS’s recognition around the issue of drug diversion is substantial and further showcases the implications this issue can have on hospitals, their staff and the patients they care for. We could not be more pleased with the positive feedback, analysis and recognition garnered by KLAS and our customers,” said Kevin MacDonald, CEO and co-founder of Kit Check. “Hospitals utilizing Bluesight have a heightened lens into the movement of their controlled substances and any medication mismanagement across the organization. These strong customer sentiments tell us that our technology is providing real value at the organizational level and validate our mission to address this important consequence of the nationwide opioid epidemic.”
Bluesight ranked first in its category in accuracy, with an 8.0 rating, and first in workflow with an 8.2 rating. From the 16-20 customers cited in the KLAS report as of May 2019 (which counts health systems as unique customers), Kit Check’s Bluesight for Controlled Substances customer base has grown to 102 hospitals spanning 30 health systems, including seven system-wide implementations.
Bluesight was the only platform to receive customer validation across all capability categories evaluated, and is one of only a few that can support both profiled access (e.g., nursing) and unprofiled access (e.g., OR) care areas. The EMR integration available with Bluesight for Controlled Substances dramatically improves customer success because it enables analytics tools to compare all drug-use data from the electronic medication administration record (eMAR) and other systems, not just dispensing systems, closing the loop on the full medication administration and management process.
According to data KLAS collected, Kit Check customers report having a strong experience overall with the software and noted its ease of use and integration tools that help users document investigation findings. Additionally, Kit Check ranked high in regard to its customer relationships, deployment process and training support. The report states that hospitals and health systems view both as essential in setting up appropriate criteria and interfaces to achieve optimized system accuracy and limit the number of false positives.
The full report is available at: https://klasresearch.com/report/drug-diversion-monitoring-2019/1570. To learn more about Kit Check’s solutions, please visit www.kitcheck.com. To learn more about KLAS, please visit http://www.klasresearch.com.
About Kit Check™
Kit Check is the leading provider of automated medication management solutions for hospital pharmacies. Our solutions blend powerful machine learning and advanced tracking technology to streamline medication inventory, workflow, and auditing processes and help hospital pharmacies cut costs, reduce risk, and get more done. To date, our more than 500 U.S. and Canadian hospital partners have tracked over 70 million medications using the Kit Check and Bluesight™ for Controlled Substances software. More information about Kit Check and our software solutions can be found at kitcheck.com.
KLAS is a research and insights firm on a global mission to improve healthcare delivery by amplifying the provider's voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software, services and medical equipment to deliver timely reports, trends and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance.
* Scores and ratings are based on conditions of limited data.